Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Evolus, Inc. Announces Full Exercise and Closing of Underwriters’ Overallotment Option
-
Max Sound Corporation Midyear Shareholder Update
-
CohBar Announces Second Quarter 2018 Financial Results
-
CohBar Announces Second Quarter 2018 Financial Results
-
Aridis Pharmaceuticals Inc. (ARDS) Prices 2M Share IPO at $13/Sh
-
Aridis Pharmaceuticals Announces Pricing of Initial Public Offering
-
Cantor Raises Envision Healthcare (EVHC) PT To Reflect KKR Deal
-
Cantor Fitzgerald Remains Bullish on Perrigo (PRGO) Despite Guidance Cut
-
Westwater Resources Reports Second Quarter 2018 Operating Results
-
Westwater Resources Reports Second Quarter 2018 Operating Results
-
Collegium Pharmaceutical (COLL) PT Lowered to $35 at Cantor Fitzgerald
-
Cantor Fitzgerald Starts Pacific Biosciences of California (PACB) at Overweight
-
Adverum Biotechnologies Reports Second Quarter 2018 Financial Results and Provides Corporate Update
-
Strongbridge Biopharma (SBBP) PT Raised to $17 at Cantor Fitzgerald
-
AcelRx Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
-
UPDATE: Cantor Fitzgerald Maintains GW Pharma (GWPH) at Overweight, Lowers PT to $211
-
Arrowhead Research (ARWR) PT Raised to $18 at Cantor Fitzgerald
-
Cantor Fitzgerald Maintains Bullish View on Opko Health (OPK) Following Beat
-
Progenics Pharma (PGNX) Prices 9.09M Share Common Offering at $8.25/Sh
-
Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Aptose Reports Results for the Second Quarter Ended June 30, 2018
-
Cantor Fitzgerald Starts HCP (HCP) at Neutral
-
Cantor Fitzgerald Starts Optinose (OPTN) at Overweight
-
Cantor Fitzgerald Starts Optinose (OPTN) at Overweight
-
Sunesis Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Highlights
-
Cara Therapeutics Reports Second Quarter 2018 Financial Results
-
Cara Therapeutics Reports Second Quarter 2018 Financial Results
-
Cantor Fitzgerald Defends Spark Therapeutics (ONCE), Saying They Didn't Expect Perfection
-
Orthofix International (OFIX) PT Raised to $66 at Cantor Fitzgerald
-
Dynavax Technologies (DVAX) PT Raised to $30 at Cantor Fitzgerald
-
TherapeuticsMD Announces Closing of its Underwritten Public Offering and Concurrent Registered Direct Offering of Common Stock
-
Aridis Pharmaceuticals Launches Proposed Initial Public Offering
-
Cantor Fitzgerald Investors, LLC, and Rodin Global Property Trust, Inc., Acquire Class A Office Building
-
HMS Holdings (HMSY) PT Raised to $26 at Cantor Fitzgerald
-
Freddie Mac Prices $599 Million K-Deal, K-W06, Supporting Affordable Multifamily Housing for Low- and Moderate-Income Working Families
-
Intercept Pharmaceuticals (ICPT) PT Raised to $69 at Cantor Fitzgerald
-
CareTrust REIT (CTRE) PT Raised to $20 at Cantor Fitzgerald
-
U.S. Physical Therapy (USPH) PT Raised to $103 at Cantor Fitzgerald
-
Tivity Health (TVTY) PT Lowered to $49 at Cantor Fitzgerald
-
Mazor Robotics (MZOR) PT Lowered to $55 at Cantor Fitzgerald
-
Allscripts (MDRX) PT Lowered to $17 at Cantor Fitzgerald
-
Computer Programs and Systems (CPSI) PT Lowered to $28 at Cantor Fitzgerald
-
MSCI Inc. (MSCI) PT Raised to $192 at Cantor Fitzgerald
-
Global Payments (GPN) PT Raised to $136 at Cantor Fitzgerald
-
CytoSorbents Achieves Record Total Revenue and CytoSorb Sales in the Second Quarter 2018
-
Teladoc (TDOC) PT Raised to $52 at Cantor Fitzgerald Following 2Q
-
Health Insurance Innovations (HIIQ) PT Raised to $65 at Cantor Fitzgerald
-
Cross Country Healthcare (CCRN) PT Lowered to $10 at Cantor Fitzgerald
-
Verisk Analytics (VRSK) PT Raised to $130 at Cantor Fitzgerald

